SION
Sionna Therapeutics, Inc.
Biotechnology
Market Cap$1.94B
5Y Perf.+214.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SION vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.+349.2%
SION vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SION | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.94B | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-75M | $-168M |
| Total Debt | $9M | $22M |
| Cash & Equiv. | $58M | $194M |
SION vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SION
DBVT
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Sionna Therapeutics… (SION) | 100 | 314.5 | +214.5% |
| DBV Technologies S.… (DBVT) | 100 | 449.2 | +349.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SION vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SION leads in 4 of 5 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
SION
Sionna Therapeutics, Inc.
The Income Pick
SION carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.14
- EPS growth -34.3%
- 73.2% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Specific-Use Pick
In this particular matchup, DBVT is outpaced on most metrics by others in the set.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | SION | 4.1% margin vs DBVT's 0.3% |
| Stability / Safety | SION | Beta 1.14 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SION | +236.3% vs DBVT's +110.4% |
| Efficiency (ROA) | SION | -21.7% ROA vs DBVT's -89.0% |
SION vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSIONLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
SIONSionna Therapeutics, …
3leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SION6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
SION6/6
Risk & VolatilityBeta, volatility, and downside exposure
SION2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SION and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | SIONSionna Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$89M | -$112M |
| Net IncomeAfter-tax profit | -$75M | -$168M |
| Free Cash FlowCash after capex | -$67M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -28.1% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SION and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SIONSionna Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $1.9B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -23.04x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 5.64x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SION and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SION leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
SION delivers a -22.9% return on equity — every $100 of shareholder capital generates $-23 in annual profit, vs $-130 for DBVT. SION carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), SION scores 5/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | SIONSionna Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -22.9% | -130.2% |
| ROA (TTM)Return on assets | -21.7% | -89.0% |
| ROICReturn on invested capital | -2.0% | — |
| ROCEReturn on capital employed | -36.4% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.13x |
| Net DebtTotal debt minus cash | -$50M | -$172M |
| Cash & Equiv.Liquid assets | $58M | $194M |
| Total DebtShort + long-term debt | $9M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
SION leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
SION leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SION five years ago would be worth $17,324 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, SION leads with a +236.3% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors SION at 20.1% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | SIONSionna Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +10.5% | +4.9% |
| 1-Year ReturnPast 12 months | +236.3% | +110.4% |
| 3-Year ReturnCumulative with dividends | +73.2% | +19.7% |
| 5-Year ReturnCumulative with dividends | +73.2% | -69.1% |
| 10-Year ReturnCumulative with dividends | +73.2% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +20.1% | +6.2% |
SION leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
SION leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SION is the less volatile stock with a 1.14 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SION currently trades 93.2% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SIONSionna Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 1.26x |
| 52-Week HighHighest price in past year | $46.46 | $26.18 |
| 52-Week LowLowest price in past year | $11.77 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +93.2% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 59.4 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 365K | 252K |
SION leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SION as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 6.8% for SION (target: $46).
| Metric | SIONSionna Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $46.25 | $46.33 |
| # AnalystsCovering analysts | 4 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SION leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). DBVT leads in 1 (Income & Cash Flow). 1 tied.
Best OverallSionna Therapeutics, Inc. (SION)Leads 3 of 6 categories
Loading custom metrics...
SION vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SION or DBVT a better buy right now?
Analysts rate Sionna Therapeutics, Inc.
(SION) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SION or DBVT?
Over the past 5 years, Sionna Therapeutics, Inc.
(SION) delivered a total return of +73. 2%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: SION returned +73. 2% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SION or DBVT?
By beta (market sensitivity over 5 years), Sionna Therapeutics, Inc.
(SION) is the lower-risk stock at 1. 14β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 11% more volatile than SION relative to the S&P 500. On balance sheet safety, Sionna Therapeutics, Inc. (SION) carries a lower debt/equity ratio of 3% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — SION or DBVT?
On earnings-per-share growth, the picture is similar: Sionna Therapeutics, Inc.
grew EPS -34. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SION or DBVT?
Sionna Therapeutics, Inc.
(SION) is the more profitable company, earning 0. 0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SION leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — SION leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SION or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SION or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Sionna Therapeutics, Inc.
(SION) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 14)). Both have compounded well over 10 years (SION: +73. 2%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SION and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.